Clinical Trial Update: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of two HIV-1 vaccine candidates, C62-M4 and C1C62-M3M4, in people with HIV-1 suppressed on ART. The study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• C1C62-M3M4
• C62-M4

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: HIV Vaccine, HIV-1-infection | Phase 1 | Status: COMPLETED | Results posted: 2025-08-24